Atopic dermatitis MedDRA version: 17.1 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858
Conditions
Sponsors
Regeneron Pharmaceuticals, Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A patient must meet the following criteria to be eligible for inclusion in the study: 1. Male or female, 18 years or older 2. Chronic AD, (according to American Academy of Dermatology Consensus Criteria [Eichenfield 2014]), that has been present for at least 3 years before the screening visit 3. EASI score =16 at the screening and baseline visits 4. IGA score =3 (on the 0 to 4 IGA scale, in which 3 is moderate and 4 is severe) at the screening and baseline visits 5. =10% body surface area (BSA) of AD involvement at the screening and baseline visits 6. Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks 7. Have applied a stable dose of topical emollient (moisturizer) twice daily for at least the 7 consecutive days immediately before the baseline visit (NOTE: See exclusion criterion #6 for limitations regarding emollients) Inclusion criteria 8-10 (see protocol section 4.2) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 550 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 50
Exclusion criteria
Exclusion criteria: A patient who meets any of the following criteria will be excluded from the study: 1.Participation in a prior dupilumab clinical study 2.Treatment with an investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer, before the baseline visit 3.Having used any of the following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, is likely to require such treatment(s) during the first 4 weeks of study treatment: •Immunosuppressive/immunomodulating drugs (eg, systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-?, Janus kinase inhibitors, azathioprine, methotrexate, etc.) •Phototherapy for AD 4.Treatment with TCS or TCI within 1 week before the baseline visit 5.Treatment with biologics as follows: •Any cell-depleting agents including but not limited to rituximab: within 6 months before the baseline visit, or until lymphocyte count returns to normal, whichever is longer • Other biologics: within 5 half-lives (if known) or 16 weeks prior to baseline visit, whichever is longer 6.Initiation of treatment of AD with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period (patients may continue using stable doses of such moisturizers if initiated before the screening visit) 7.Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the baseline visit 8.Planned or anticipated use of any prohibited medications (see section 5.7.1) and procedures during study treatment 9.Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit 10.Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit. NOTE: patients may be rescreened after infection resolves. 11.Known or suspected history of immunosuppression, including history of invasive opportunistic infections (eg, tuberculosis [TB], histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution: or unusually frequent, recurrent, or prolonged infections, per investigator judgment 12.History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening 13.Positive with hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody at the screening visit All the exclusion criteria are listed in protocol section 4.2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of the study is to demonstrate the efficacy of dupilumab monotherapy compared to placebo treatment in adult patients with moderate-to-severe AD.;Secondary Objective: The secondary objective of the study is to assess the safety of dupilumab monotherapy compared to placebo treatment in patients with moderate-to-severe AD.;Timepoint(s) of evaluation of this end point: The primary endpoint will be determined at week 16.;Primary end point(s): • Proportion of patients with both IGA 0 to 1 (on a 5-point scale) and a reduction from baseline of =2 points at week 16 For the European Medicines Agency (EMA) and EMA Reference Market Countries only, the co primary endpoints are: • Proportion of patients with EASI-75 (=75% improvement from baseline) at week 16 • Proportion of patients with both IGA 0 to 1 (on a 5-point scale) and a reduction from baseline of =2 points at week 16 | — |
Secondary
| Measure | Time frame |
|---|---|
| Timepoint(s) of evaluation of this end point: The secondary endpoints will be determined from baseline to week 16.;Secondary end point(s): • Proportion of patients with EASI-75 (=75% improvement from baseline) at week 16 (this is not a secondary endpoint for the EMA as it is already a co-primary endpoint) • Percent change from baseline to week 16 in pruritus NRS • Proportion of patients with improvement (reduction) of pruritus NRS =3 from baseline to week 16 • Percent change in EASI score from baseline to week 16 • Change from baseline to week 16 in percent BSA • Change from baseline to week 16 in SCORAD • Change from baseline to week 16 in GISS (erythema, infiltration/papulation, excoriations, lichenification) • Change from baseline to week 16 in DLQI • Change from baseline to week 16 in HADS • Change from baseline to week 16 in POEM • Percent change from baseline to week 2 in pruritus NRS • Incidence of skin infection treatment-emergent adverse events (TEAE) requiring systemic treatment from baseline through week 16 • Incidence of treatment-emergent serious adverse events (TESAEs) from baseline through week 16 • Incidence of TEAEs leading to treatment discontinuation from baseline through week 16 • Overall incidence of TEAEs through week 16 | — |
Countries
Bulgaria, Canada, Denmark, Estonia, Finland, France, Germany, Hong Kong, Italy, Korea, Republic of, Lithuania, Poland, Spain, Sweden, United Kingdom, United States
Contacts
Public ContactClinical Trials information
Regeneron Pharmaceuticals, Inc.
Outcome results
None listed